The treatment pathway for postmeonopausal women with osteoporosis has changed with the emergence of two new anabolic treatments approved by NICE (romosozumab and abaloparatide). This teaching will educate practitioners about which patients should be considered for these treatments over oral bisphosphonates.
Speaker(s)
Dr Vera Choida